Ginkgo Bioworks Holdings Management
Management criteria checks 3/4
Ginkgo Bioworks Holdings' CEO is Jason Kelly, appointed in Jan 2008, has a tenure of 16.42 years. total yearly compensation is $262.50K, comprised of 95.2% salary and 4.8% bonuses, including company stock and options. directly owns 3.87% of the company’s shares, worth $31.33M. The average tenure of the management team and the board of directors is 5.9 years and 2.3 years respectively.
Key information
Jason Kelly
Chief executive officer
US$262.5k
Total compensation
| CEO salary percentage | 95.2% |
| CEO tenure | 16.4yrs |
| CEO ownership | 3.9% |
| Management average tenure | 5.9yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
Ginkgo Bioworks: Losing A Major Supporter
Jun 25Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Jun 18
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Ginkgo Bioworks launches Ginkgo Enzyme Services
Dec 08Ginkgo, Lygos team up to produce sustainable biobased specialty chemicals
Nov 11Ginkgo, Draper develop new technologies to detect engineered DNA
Oct 17Ginkgo stock rises on acquisition of French biotech Altar
Oct 04Ginkgo Bioworks: Promising Upside But Not Without Risks
Sep 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$854m |
| Dec 31 2023 | US$263k | US$250k | -US$893m |
| Sep 30 2023 | n/a | n/a | -US$857m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$263k | US$250k | -US$2b |
| Sep 30 2022 | n/a | n/a | -US$4b |
| Jun 30 2022 | n/a | n/a | -US$3b |
| Mar 31 2022 | n/a | n/a | -US$2b |
| Dec 31 2021 | US$381m | US$250k | -US$2b |
| Sep 30 2021 | n/a | n/a | -US$276m |
| Jun 30 2021 | n/a | n/a | -US$200m |
| Mar 31 2021 | n/a | n/a | -US$175m |
| Dec 31 2020 | US$11m | US$250k | -US$127m |
Compensation vs Market: Jason's total compensation ($USD262.50K) is below average for companies of similar size in the US market ($USD3.43M).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
CEO
Jason Kelly (43 yo)
16.4yrs
Tenure
US$262,500
Compensation
Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) in 2008 and serves as its Chief Executive Officer and has been Director s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.4yrs | US$262.50k | 3.87% $ 31.3m | |
| Founder | 16.4yrs | US$262.50k | 4.21% $ 34.1m | |
| Chief Financial Officer | 3.6yrs | US$1.69m | 0.073% $ 589.6k | |
| Founder | no data | no data | 0% $ 0 | |
| Founder | no data | no data | 4.32% $ 35.0m | |
| Founder | no data | no data | 4.2% $ 34.0m | |
| Chief Accounting Officer | 1.1yrs | no data | 0.0081% $ 65.5k | |
| General Counsel & Secretary | no data | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Head of People | 6.4yrs | no data | no data | |
| Head of Design | 5.7yrs | no data | no data | |
| Head of Omics & Analytical Chemistry | 5.9yrs | no data | no data |
5.9yrs
Average Tenure
43yo
Average Age
Experienced Management: DNA's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.4yrs | US$262.50k | 3.87% $ 31.3m | |
| Founder | 16.4yrs | US$262.50k | 4.21% $ 34.1m | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Independent Director | 2.8yrs | US$459.38k | 0.037% $ 301.6k | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Independent Director | 8.4yrs | US$477.50k | 0.061% $ 490.6k | |
| Independent Director | 1.8yrs | US$448.67k | 0.0076% $ 61.2k | |
| Independent Director | 2.8yrs | US$457.50k | 0.031% $ 254.5k | |
| Independent Chairman of the Board | 9.4yrs | US$485.19k | 0.11% $ 901.6k | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Member of Biopharma Advisory Board | less than a year | no data | no data |
2.3yrs
Average Tenure
62yo
Average Age
Experienced Board: DNA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.